Bayer AG - Product Pipeline Review - 2012

Global Markets Direct, September 2012, Pages: 443

Bayer AG – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Bayer AG - Product Pipeline Review - 2012” provides data on the Bayer AG’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Bayer AG’s corporate website, SEC filings, investor presentations and featured press releases, both from Bayer AG and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Bayer AG - Brief Bayer AG overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Bayer AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Bayer AG with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Bayer AG’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Bayer AG’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Bayer AG in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Bayer AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Bayer AG.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Bayer AG and identify potential opportunities in those areas.

2
List of Tables 4
List of Figures 7
Bayer AG Snapshot 9
Bayer AG Overview 9
Key Information 9
Key Facts 9
Bayer AG – Research and Development Overview 10
Key Therapeutic Areas 10
Bayer AG – Pipeline Review 16
Pipeline Products by Stage of Development 16
Pipeline Products – Monotherapy 17
Pipeline Products – Combination Treatment Modalities 18
Bayer AG – Pipeline Products Glance 19
Bayer AG – Late Stage Pipeline 19
Bayer AG Clinical Stage Pipeline Products 22
Bayer AG – Early Stage Pipeline Products 28
Bayer AG – Drug Profiles 29
aflibercept 29
Alpharadin + Taxotere 31
amikacin 33
aspirin 35
Autologous Recombinant Idiotypic Vaccine 36
BAY 80-6946 + Paclitaxel 37
BAY-1000394 38
BAY-1000394 + Carboplatin + Etoposide 39
BAY-1001931 40
BAY-1002670 41
BAY-1021189 42
BAY-1067197 43
BAY-1082439 44
BAY-80-6946 45
BAY-806946 + Gemcitabine 46
BAY-806946 + Gemcitabine + Cisplatin 47
BAY-81-8973 49
BAY-85-3934 51
BAY-86-6150 53
BAY-86-9766 + Gemcitabine 55
BAY-868050 57
BAY-87-2243 58
BAY-94-8862 59
BAY-94-9027 60
BAY-94-9343 61
BAY-97-2243 62
BAY1000394 + Cisplatin + Etoposide 63
BAY60-4552 + Vardenafil 64
BAY80-6946 + BAY86-9766 66
BAY86-9766 + Nexavar 67
BR-5489 69
ciprofloxacin 71
FC Patch Low 73
lonaprisan 75
mapracorat 76
Modified FOLFOX6 + Nexavar 78
Nexavar + Paclitaxel + Carboplatin + Bevacizumab 80
Nexavar + Capecitabine 82
Nexavar + Dacarbazine 84
Nexavar + Tarceva 86
Nifedipine GITS + Candesartan 87
prasterone 88
radium Ra 223 dichloride 90
refametinib 92
regorafenib 94
Regorafenib + Cisplatin + Pemetrexed 96
Regorafenib + FOLFIRI 98
Regorafenib + mFOLFOX6 100
riociguat 102
rivaroxaban 104
Selective Kinase Inhibitor Program 106
SMOLs 107
sodium desoxycholate 108
sorafenib tosylate 110
torezolid 112
YAZ-Flex 114
Bayer AG – Pipeline Analysis 116
Bayer AG – Pipeline Products by Therapeutic Class 116
Bayer AG – Pipeline Products By Target 117
Bayer AG – Pipeline Products by Route of Administration 118
Bayer AG – Pipeline Products By Mechanism of Action 119
Bayer AG – Recent Pipeline Updates 121
Bayer AG - Dormant Projects 147
Bayer AG - Discontinued Pipeline Products 150
Discontinued Pipeline Product Profiles 150
Bayer AG – Company Statement 152
Bayer AG – Locations And Subsidiaries 155
Head Office 155
Other Locations & Subsidiaries 155
Bayer AG, Recent Developments 162
Bayer AG- Press Release 162
Financial Deals Landscape 233
Bayer AG, Deals Summary 233
Bayer AG, Pharmaceuticals & Healthcare, Deal Details 240
Asset Transactions 240
Venture Financing 247
Partnerships 249
Licensing Agreements 332
Equity Offering 365
Debt Offering 367
Asset Transactions 395
Acquisition 410
Appendix 433
Methodology 433
Coverage 433
Secondary Research 433
Primary Research 433
Expert Panel Validation 433
Contact Us 434
Disclaimer 434

List of Tables
Bayer AG, Key Information 18
Bayer AG, Key Facts 18
Bayer AG – Pipeline by Indication, 2012 21
Bayer AG – Pipeline by Stage of Development, 2012 25
Bayer AG – Monotherapy Products in Pipeline, 2012 26
Bayer AG – Combination Treatment Modalities in Pipeline, 2012 27
Bayer AG – Filed, 2012 28
Bayer AG – Phase III, 2012 29
Bayer AG – Phase II, 2012 31
Bayer AG – Phase I, 2012 34
Bayer AG – Pre-Clinical, 2012 37
Bayer AG – Pipeline By Therapeutic Class, 2012 125
Bayer AG - Pipeline By Target, 2012 126
Bayer AG – Pipeline By Route of Administration, 2012 127
Bayer AG – Pipeline Products By Mechanism of Action, 2012 129
Bayer AG – Recent Pipeline Updates, 2012 130
Bayer AG - Dormant Developmental Projects,2012 156
Bayer AG - Discontinued Pipeline Products, 2012 159
Bayer AG, Subsidiaries 164
Bayer AG, Deals Summary 242
Bayer HealthCare Acquires Western OTC Cough And Cold Business From Topsun Science and Technology 249
Bayer HealthCare Acquires MAXY-VII From Maxygen 251
Bayer HealthCare Acquires OTC Business Of Sagmel 253
Bayer HealthCare Acquires Citracal From Mission Pharmacal Company 255
AiCuris Raises $75 Million In Second Round Of Venture Financing 256
MEDRAD Enters Into Licensing Agreement With B. Braun Melsungen 258
Bayer HealthCare Enters Into Licensing And Collaboration Agreement With Nuvelo 260
Bayer HealthCare Enters Into Co-Marketing Agreement With Radimetrics For eXposure 262
Bayer HealthCare Enters Into Agreement With Covance 263
Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 264
Bayer HealthCare Enters Into Co-Development Agreement With Amgen Research 269
Bayer Healthcare Enters Into Co-Development Agreement With Tsinghua University 270
Bayer Yakuhin Enters Into Distribution Agreement With Femasys For FemVue Saline-Air Device 271
Bayer HealthCare And Almirall Enter Into Co-Promotion Agreement For Rivaroxaban In Spain 272
Ventana Medical Systems Enters Into Co-Development Agreement With Bayer Pharma 273
MediSapiens Enters Into Co-Development Agreement With Bayer HealthCare Pharma 275
Dong-A Pharma Enters Into Co-Marketing Agreement With Bayer Korea 276
Bayer Enters Into Research Agreement With Ludwig Boltzmann, Nebu-Tec, And Austrian Academy 277
Bayer Vital Signs Agreement With Vital Images 279
Bayer HealthCare Enters Into Joint Venture Agreement With Zydus Cadila Healthcare 280
Bayer HealthCare Enters Into Research Agreement With University of California 299
HANDOK Pharma Enters Into Co-Marketing Agreement With Bayer Korea 300
Cancer Targeted Enters Into Research And License Option Agreement With Bayer Pharma 301
Bayer HealthCare Enters Into An Agreement With NUS, NUHS, SingHealth And SBIC 302
MEDRAD Enters Into A Distribution Agreement With WFR-AQUAPLAST And Qfix Systems 304
Merge Healthcare Expands European Distribution Agreement With MEDRAD 305
MEDRAD Enters Into Research Agreement With The University of South Florida And Moffitt Cancer Center 306
HRA Pharma Enters Into Agreement with Bayer 307
Neptune Technologies Enters Into An Agreement With Bayer Healthcare 308
Neptune Technologies & Bioressources Signs An Agreement With Bayer Healthcare 309
Bayer CropScience Enters Into Research Agreement With IVCC 310
Bayer HealthCare Extends Collaboration With Regeneron Pharma 311
Bayer HealthCare Enters Into Joint Venture Agreement With Tsinghua University 315
MEDRAD Signs Research Agreement With University of Zurich 316
Tyrian Diagnostics Enters Into Co-Development Agreement With Bayer CropScience 317
innovatis Enters Into Co-Marketing Agreement With Bayer Technology Services 318
Sartorius Stedim Biotech Enters Into Co-Marketing Agreement With Bayer Technology Services 319
Confirma Signs An Agreement With MEDRAD 320
Fujifilm RI Pharma Enters Into Co-Marketing Agreement With Bayer Yakuhin For Zevalin 321
AmVac Enters Into Research Agreement With Icon Genetics 322
MEDRAD Enters Into A Distribution Agreement With PETNET Solutions 323
Mitsubishi Tanabe Enters Into Co-Marketing Agreement With Bayer Yakuhin 324
MEDRAD Signs An Agreement With Abbott Point of Care 325
Bayer CropScience Enters Into Research Agreement With IVCC 326
Nektar Therapeutics Enters Into Co-Development Agreement With Bayer HealthCare 327
Bayer HealthCare Enters Into Co-Promotion Agreement With Intendis 329
Bayer Yakuhin Enters Into Agreement With Intendis 330
KineMed Enters Into Co-Development Agreement With Bayer HealthCare 331
CSL Behring Enters Into Distribution Agreement With Bayer HealthCare 332
Chongkundang Enters Into Co-Marketing Agreement With Bayer HealthCare 333
Regeneron Pharma Enters Into Collaboration Agreement With Bayer HealthCare 334
Bayer Enters Into Distribution Agreement With Teva Canada 336
Nippon Shinyaku Enters Into An Agreement With Bayer Yakuhin 337
Nektar Therapeutics Signs Co-Development Agreement With Bayer HealthCare 338
Caprion Pharma Enters Into Co-Development Agreement With Bayer HealthCare 340
KINAXO Biotechnologies Enters Into A Licensing Agreement With Bayer Vital 341
Barr Labs Enters Into Licensing Agreement With Bayer 342
Clontech Enters Into Licensing Agreement With Bayer HealthCare 343
Serologicals Enters Into License Agreement With Bayer Pharma 344
Bayer HealthCare Enters Into Licensing Agreement With OriGene Technologies 345
Spectrum Pharma Enters Into Licensing Agreement With Bayer Healthcare For Zevalin 346
Trius Therapeutics Enters Into Licensing Agreement With Bayer HealthCare For Torezolid Phosphate 348
Stellar Biotechnologies Enters Into Licensing Agreement With Bayer Innovation 350
SentiSearch Enters Into Licensing Agreement With Bayer CropScience, Columbia University And Rockefeller University 351
Cellectis Enters Into Licensing Agreement With Bayer HealthCare 353
Ardea Biosciences Enters Into License Agreement With Bayer HealthCare 354
ImmunoGen Enters Into Licensing Agreement With Bayer HealthCare 356
Activaero Enters Into Licensing Agreement With Bayer HealthCare 357
Sonus Pharma Enters Into Licensing Agreement With Bayer Healthcare 358
Maxygen Enters Into License Agreement With Bayer HealthCare 359
Barr Labs Enters Into Licensing Agreement With Bayer For Yasmin And Yaz 360
Seattle Genetics Amends Licensing Agreement With Bayer HealthCare 362
ACT Biotech Enters Into Licensing Agreement With Bayer HealthCare 363
BioInvent International Signs Licensing Agreement With Bayer HealthCare 364
Millipore Enters Into Licensing Agreement With Bayer HealthCare 365
Ariadne Extends License Agreement With Bayer 366
Aureus Pharma Enters Into Licensing Agreement With Bayer CropScience 367
CSL Behring Enters Into Licensing Agreement With Bayer 368
BIOBASE Enters Into Licensing Agreement With Bayer Healthcare 369
Biocon Enters Into Licensing Agreement With Bayer HealthCare For INSUGEN 370
Bayer Pharma Enters Into Licensing Agreement With Pfizer 371
Bayer Healthcare Enters Into Licensing Agreement With Signet Labs 373
Bayer Completes Private Placement Of $1,473 Million 374
Bayer Holding Completes Public Offering Of 0.82% Corporate Bonds Due 2017 For $363 Million 376
Bayer Holding Completes Public Offering Of 1.46% Corporate Bonds Due 2017 For $109 Million 378
Bayer Completes Public Offering Of 4.625% Bond For $1,776 Million 380
Bayer Completes Public Offering Of 4% Bonds For $284 Million 381
Bayer Completes Public Offering Of 3.575% Bonds For $170 Million 383
Bayer Completes Public Offering Of Floating Rate Bonds For $94.11 Million 385
Bayer Completes Public Offering Of 1.585% Bonds For $81.48 Million 387
Bayer Completes Public Offering Of 1.955% Bonds For $122.23 Million 389
Bayer Completes Public Offering Of Floating Rate Bonds For $244.45 Million 391
Bayer Completes Public Offering Of Fixed Rate Bonds For $267 Million 393
Bayer Completes Public Offering Of Floating Rate Bonds For $401 Million 395
Bayer Completes Public Offering Of 4.5% Bonds For $1,272.16 Million 397
Bayer Completes Public Offering Of 5.625% Bonds For $652.95 Million 399
Bayer Completes Public Offering Of Floating Rate Bonds For $2,044.51 Million 401
Bayer Completes Private Placement Of 6.625% Bonds For $2,769.29 Million 403
Nordic Group To Acquire Trasylol From Bayer HealthCare 404
Siemens Healthcare Diagnostics Completes Acquisition Of Manufacturing Plant In Mishawaka From Bayer HealthCare 405
Naari Acquires Visanne Brand From Bayer 406
Genzyme Acquires Rights To Fludara And Leukine From Bayer HealthCare 407
Genzyme Completes Acquisition Of Leukine Manufacturing Facility From Bayer HealthCare For $98.5 Million 409
Genzyme Acquires Rights To Campath From Bayer HealthCare 411
Axxam Acquires Molecular Screening Technologies From Bayer HealthCare 413
Bayer HealthCare Sells Its Plasma Products Business To Talecris BioTherapeutics 414
Siemens Medical Solutions Acquires Diagnostics Division Of Bayer Healthcare 416
Delpharm Acquires Manufacturing Plant From Schering 418
Delpharm Completes Acquisition Of Bayer Sante Familiale, Consumer Care Division Of Bayer 419
Nomad Bioscience Acquires Icon Genetics From Bayer Innovation 421
MEDRAD Completes Acquisition Of Pathway Medical Technologies For $125 Million 423
Bayer MaterialScience Acquires Artificial Muscle 426
Bayer Acquires Remaining 49% Interest In Berlimed From Juste 427
Juste Acquires 51% Interest In Justesa Imagen From Bayer 428
Bayer HealthCare Completes Acquisition Of iSense 430
Bayer Acquires Minority Stake In Bayer Schering Pharma 431
Bayer HealthCare Acquires DIREVO Biotech 432
MEDRAD Completes Acquisition Of Possis Medical 435
Bayer Acquires Schering 437
Santo Holding Acquires Majority Stake In AiCuris 439
Bayer Acquires Icon Genetics 440

List of Figures
Bayer AG – Pipeline by Indication, 2012 21
Bayer AG – Pipeline by Stage of Development, 2012 25
Bayer AG – Monotherapy Products in Pipeline, 2012 26
Bayer AG – Combination Treatment Modalities in Pipeline, 2012 27
Bayer AG – Pipeline By Therapeutic Class, 2012 125
Bayer AG – Pipeline By Route of Administration, 2012 127
Bayer AG - Pipeline Products By Mechanism of Action, 2012 128

Customers who bought this item also bought

• eBay - Strong Execution
• Fortis Healthcare Limited - IT Sales Opportunities - 2009
• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apollo Hospitals Enterprise Limited - IT Sales Opportunities - 2009
• Wincor Nixdorf AG
• Bechtle AG
• eBay Inc,(EBAY) Profile and Financials, plus E-Commerce & Internet Industry Trends Analysis, Operating Ratio and Financial Averages
• SAP AG,(SAP) Profile and Financials, plus E-Commerce & Internet Industry Trends Analysis, Operating Ratio and Financial Averages
• Siemens AG,(SI) Profile and Financials, plus E-Commerce & Internet Industry Trends Analysis, Operating Ratio and Financial Averages
• United Internet AG,(UDIRF) Profile and Financials, plus E-Commerce & Internet Industry Trends Analysis, Operating Ratio and Financial Averages